1. Home
  2. CRBU vs JHS Comparison

CRBU vs JHS Comparison

Compare CRBU & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$1.24

Market Cap

138.3M

Sector

Health Care

ML Signal

N/A

Logo John Hancock Income Securities Trust

JHS

John Hancock Income Securities Trust

N/A

Current Price

$10.43

Market Cap

126.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBU
JHS
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
138.3M
126.9M
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
CRBU
JHS
Price
$1.24
$10.43
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $11.86
N/A
AVG Volume (30 Days)
★ 1.0M
11.3K
Earning Date
11-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 3.64
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$128.04
N/A
Revenue Next Year
$17.09
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$10.36
52 Week High
$3.53
$12.09

Technical Indicators

Market Signals
Indicator
CRBU
JHS
Relative Strength Index (RSI) 37.24 22.35
Support Level N/A N/A
Resistance Level $1.74 $11.01
Average True Range (ATR) 0.05 0.08
MACD 0.00 -0.01
Stochastic Oscillator 32.14 0.00

Price Performance

Historical Comparison
CRBU
JHS

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

Share on Social Networks: